Cytek Biosciences Inc Reports Q3 2026 Revenue of $53.2 Million, GAAP EPS of -$0.06 Beats Estimates
Gross Margin Expansion Offsets Wider Net Loss as Recurring Revenue Builds Related Stocks: CTKB ,
Gross Margin Expansion Offsets Wider Net Loss as Recurring Revenue Builds Related Stocks: CTKB ,